Friday, 10 Oct 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    Fintech Forward 2025 Delivers with 38 Industry-Shaping Partnerships and Strategic Agreements Signed
    Fintech Forward 2025 Delivers with 38 Industry-Shaping Partnerships and Strategic Agreements Signed
    10/10/2025
    Kimberly-Clark Launches Enhanced Global Partnerships to Advance Essential Care for 24 Million Women and Girls
    Kimberly-Clark Launches Enhanced Global Partnerships to Advance Essential Care for 24 Million Women and Girls
    10/10/2025
    GEDU Group to Become Largest Foreign Education Investor in India
    GEDU Group to Become Largest Foreign Education Investor in India
    09/10/2025
    Signs of Change: Equipping Teachers with Tools for Inclusive Classrooms
    Signs of Change: Equipping Teachers with Tools for Inclusive Classrooms
    09/10/2025
    Nobel Prize 2025 in Medicine: Three Scientists Who Changed the Future of Immunology
    Nobel Prize 2025 in Medicine: Three Scientists Who Changed the Future of Immunology
    08/10/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • global
  • Business
  • june
  • announced
  • today
  •  and
  •  the
  • july
  • company
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

Intas Pharmaceuticals Launches HETRONIFLY (Serplulimab), India’s First Novel Immunotherapy for Advanced Small Cell Lung Cancer

PRNW Agency
Last updated: 06/08/2025 8:32 AM
PRNW Agency
Share
2 Min Read
Intas Pharmaceuticals Launches HETRONIFLY (Serplulimab), India’s First Novel Immunotherapy for Advanced Small Cell Lung Cancer
SHARE
Intas Pharmaceuticals Launches HETRONIFLY (Serplulimab), India’s First Novel Immunotherapy for Advanced Small Cell Lung Cancer

AHMEDABAD, India, Aug. 5, 2025 /PRNewswire/ — Intas Pharmaceuticals has launched HETRONIFLY™ (Serplulimab), the first PD-1 inhibitor globally approved for the treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC), in the Indian market. This marks another major milestone, following the successful Launch in Europe.

- Advertisement -

This launch follows a strategic licensing agreement between Intas Pharmaceuticals Limited and Shanghai Henlius Biotech, Inc., further strengthening Intas’ oncology portfolio and reinforcing its commitment to delivering cutting-edge therapies to patients in India.

- Advertisement -

Serplulimab is the first PD-1 inhibitor worldwide to receive approval for ES-SCLC, and is currently present in over 40 countries, including key European markets. Its efficacy is supported by the landmark ASTRUM-005 trial, which demonstrated a 40% reduction in the risk of death and remarkably higher overall survival rate versus the current standard-of-care Chemotherapy regimen. Notably, Serplulimab achieved an ESMO-MCBS score of 4/5—the highest among current immunotherapies, signifying highest clinical benefit in this indication.

- Advertisement -

The novel humanized mAb has a unique dual-blockade mechanism of PD-L1 and PD-L2, along with the highest PD-1 internalization, which sets a new benchmark in deep immune engagement for solid tumors. Globally, Serplulimab has been administered to over a lakh patients across a range of malignancies including SCLC, NSCLC, ESCC, and MSI-high cancers.

- Advertisement -

Despite the promise of immuno-oncology, cost remains a significant barrier in India. HETRONIFLY™, introduced at approximately 75% lower cost than the currently available immunotherapies for this indication, underscores Intas’ commitment to providing high-quality innovative therapies at affordable prices to cancer patients in India.

- Advertisement -

Commenting on the launch, Binish Chudgar, Chairman & Managing Director of Intas Pharmaceuticals said, “The launch of HETRONIFLY™ reinforces our strategic position in oncology and reflects Intas’ commitment to accelerating access to globally validated therapies. It aligns with our operating model of delivering high-impact innovations to the Indian market with speed and cost-efficiency.”

- Advertisement -

Logo: https://mma.prnewswire.com/media/2514170/4930499/Intas_Accord_Logo.jpg

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.com/in/news-releases/intas-pharmaceuticals-launches-hetronifly-serplulimab-indias-first-novel-immunotherapy-for-advanced-small-cell-lung-cancer-302522015.html

- Advertisement -
Godrej Properties’ CREW Conclave 2025 Celebrates One Year of Impact with ‘Echoes of the Firsts’
Indian Researchers Call for Balanced and Responsible Research Assessments: Springer Nature Survey Reveals Global Insights
Plexigrid Appoints Peter Tornberg as Chief Operating Officer to Drive Global Scale-Up of its Grid Intelligence and Orchestration Platform
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Hisense named global fastest growing soundbar brand in the past 5 years
TAGGED: for(serplulimab),advancedahmedabadanotherapprovedaugcancercellcurrentessclcextensivestagefirstfollowinggloballyhetroniflyhighestimmunotherapyindia:india’sindianinhibitorintaslaunchlaunchedlauncheslungmajormarketmarksmilestonenewsnovelpharmaceuticalssmallsuccessfultreatment
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

PART TWO: A DECADE OF VISION  THE 10 MOST ICONIC GENESIS CONCEPT CARS
Automobile

PART TWO: A DECADE OF VISION THE 10 MOST ICONIC GENESIS CONCEPT CARS

02/08/2025
The 8th WeddingSutra Influencer Awards to be held on August 20 at The Taj Mahal Palace, Mumbai
News

The 8th WeddingSutra Influencer Awards to be held on August 20 at The Taj Mahal Palace, Mumbai

08/08/2025
H2Ok Innovations Rebrands as Laminar, Pioneering Closed-loop AI for Autonomous CPG Manufacturing
Business

H2Ok Innovations Rebrands as Laminar, Pioneering Closed-loop AI for Autonomous CPG Manufacturing

03/10/2025
Growth Hackers Strengthens Market Position Through Strategic Lovable Partnership for Advanced SEO Solutions
Tech

Growth Hackers Strengthens Market Position Through Strategic Lovable Partnership for Advanced SEO Solutions

20/08/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?